Meeting
2014 Breast Cancer Symposium
Tumor infiltrating lymphocytes (TIL) predict response to neoadjuvant chemotherapy in breast cancer: A systemic review and meta-analysis.
Authors
Yan Mao
Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yan Mao , Qing Qu , Yuzi Zhang , Junjun Liu , Kunwei Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
Advanced Disease
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 138)
DOI
10.1200/jco.2014.32.26_suppl.138
Abstract #
138
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.
First Author: Arya Mariam Roy
Poster
2020 ASCO Virtual Scientific Program
Liquid biopsy of the immune environment: Evaluation of peripheral blood mononuclear cells (PBMCs) with CyTOF and response to trastuzumab (T)-based neoadjuvant chemotherapy (NAC) in HER2+ breast cancer (BC).
First Author: Roberto Antonio Leon-Ferre
Poster
2016 ASCO Annual Meeting
Association between distinct intratumoral and stromal tumor infiltrating immune cells and pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
First Author: Lucia Gonzalez-Cortijo
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel